摘要
目的 评价替吉奥（S-1）联合奈达铂方案治疗晚期转移性鼻咽癌的临床疗效及毒副反应.方法 晚期转移性鼻咽癌患者40例,根据数字表法随机分为两组,观察组19例给予S-1联合奈达铂治疗,对照组21例采用吉西他滨联合奈达铂治疗,按实体瘤疗效评价标准（RECIST）评价两组有效率（RR）、无进展生存期（PFS）和不良反应.结果 观察组、对照组RR分别为52.6％、52.3％,PFS分别5.5个月、5.2个月,两组差异均无统计学意义（均P＞0.05）;观察组、对照组Ⅲ～Ⅳ度血小板下降率分别为10.5％、38.0％,两组差异有统计学意义（Х^2 =4.89,P＜0.05）,其他不良反应均可以耐受.结论 S-1联合奈达铂治疗晚期转移性鼻咽癌的近期临床疗效与吉西他滨联合奈达铂相似,但不良反应较轻,患者依从性好,值得临床进一步研究验证.
Objective To evaluate the efficacy and toxicity of gimeracil and oteracil porassium capsules combined with nedaplatin in the treatment of the patients with distant metastatic nasopharyngeal carcinoma.Methods Fourty cases were randomly divided into the observation group and control group by random digital table.19 cases in the observation group were treated with oteracil potassium capsules combined with nedaplatin.21cases in the observation group were treated with gemcitabine combined with nedaplatin.The response rate,response rate（RR） and progression free survival（PFS）,toxicity were evaluated according to response evaluation criteria in solid tumors （RECIST）.Results The response rate were 52.6%,52.3% respectively,the median progression-free survival were 5.5 and 5.2 months,respectively.Grade Ⅲ an Ⅳ platelet supression were 10.5%,38.0% between the observation group and control group.It was statistically significant between the two group（Х^2 =4.89,P 〈 0.05）.Conclusion Oteracil porassium capsules combined with nedaplatin is similar with gemcitabine combined with nedaplatin in the distant metastatic nasopharyngeal carcinoma,the adverse reaction was lighter than that of the control group.
出处
《中国基层医药》
CAS
2015年第1期11-14,共4页
Chinese Journal of Primary Medicine and Pharmacy
关键词
鼻咽肿瘤
转移
替吉奥
奈达铂
nasopharyngeal
metastasis
gimeracil and oteracil porassium capsules
nedaplatin
gemcitabine
efficacy
